CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade X4 Pharmaceuticals, Inc. - XFOR CFD

    0.83
    3.49%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026346 %
    Charges from full value of position ($-5.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026346%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004124 %
    Charges from full value of position ($0.78)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    X4 Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.86
    Open* 0.86
    1-Year Change* -31.75%
    Day's Range* 0.83 - 0.87
    52 wk Range 0.65-2.58
    Average Volume (10 days) 1.75M
    Average Volume (3 months) 32.83M
    Market Cap 134.02M
    P/E Ratio -100.00K
    Shares Outstanding 167.29M
    Revenue N/A
    EPS -0.79
    Dividend (Yield %) N/A
    Beta 0.64
    Next Earnings Date Mar 19, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 5, 2023 0.86 0.05 6.17% 0.81 0.90 0.78
    Dec 4, 2023 0.79 0.09 12.86% 0.70 0.80 0.68
    Dec 1, 2023 0.71 -0.03 -4.05% 0.74 0.74 0.68
    Nov 30, 2023 0.75 0.00 0.00% 0.75 0.78 0.73
    Nov 29, 2023 0.72 -0.03 -4.00% 0.75 0.76 0.72
    Nov 28, 2023 0.75 0.00 0.00% 0.75 0.75 0.73
    Nov 27, 2023 0.75 -0.02 -2.60% 0.77 0.79 0.75
    Nov 24, 2023 0.76 0.03 4.11% 0.73 0.78 0.73
    Nov 22, 2023 0.74 -0.02 -2.63% 0.76 0.78 0.73
    Nov 21, 2023 0.77 -0.01 -1.28% 0.78 0.78 0.74
    Nov 20, 2023 0.77 0.01 1.32% 0.76 0.81 0.76
    Nov 17, 2023 0.76 0.01 1.33% 0.75 0.78 0.74
    Nov 16, 2023 0.73 -0.03 -3.95% 0.76 0.77 0.73
    Nov 15, 2023 0.76 -0.01 -1.30% 0.77 0.81 0.75
    Nov 14, 2023 0.78 0.01 1.30% 0.77 0.80 0.76
    Nov 13, 2023 0.74 0.00 0.00% 0.74 0.75 0.69
    Nov 10, 2023 0.73 -0.04 -5.19% 0.77 0.79 0.73
    Nov 9, 2023 0.76 0.03 4.11% 0.73 0.78 0.68
    Nov 8, 2023 0.71 -0.09 -11.25% 0.80 0.80 0.70
    Nov 7, 2023 0.78 -0.03 -3.70% 0.81 0.83 0.78

    X4 Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Tuesday, March 19, 2024

    Time (UTC)

    12:30

    Country

    US

    Event

    Q4 2023 X4 Pharmaceuticals Inc Earnings Release
    Q4 2023 X4 Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 3 0 3.5
    Total Operating Expense 87.569 85.107 63.036 52.269 49.385
    Selling/General/Admin. Expenses, Total 27.02 24.702 20.942 16.64 18.406
    Research & Development 61.058 50.647 41.932 30.163 30.979
    Unusual Expense (Income) -0.509 9.758 0.162 5.466 0
    Operating Income -87.569 -85.107 -60.036 -52.269 -45.885
    Interest Income (Expense), Net Non-Operating -2.073 -3.998 -2.852 -0.767 -0.23
    Other, Net -4.197 0.426 0.905 0.229 3.094
    Net Income Before Taxes -93.839 -88.679 -61.983 -52.807 -43.021
    Net Income After Taxes -93.867 -88.696 -62.131 -52.807 -43.021
    Net Income Before Extra. Items -93.867 -88.696 -62.131 -52.807 -43.021
    Net Income -93.867 -88.696 -62.131 -52.807 -43.021
    Total Adjustments to Net Income -2.546 -13.943 0 -0.592 0
    Income Available to Common Excl. Extra. Items -96.413 -102.639 -62.131 -53.399 -43.021
    Income Available to Common Incl. Extra. Items -96.413 -102.639 -62.131 -53.399 -43.021
    Dilution Adjustment
    Diluted Net Income -96.413 -102.639 -62.131 -53.399 -43.021
    Diluted Weighted Average Shares 63.526 25.749 20.077 11.53 2.38466
    Diluted EPS Excluding Extraordinary Items -1.51769 -3.98614 -3.09464 -4.63131 -18.0408
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -1.5229 -3.73981 -3.08939 -4.15724 -16.573
    Revenue 0 0 3 3.5
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue
    Total Operating Expense 25.805 29.304 25.577 20.154 20.57
    Selling/General/Admin. Expenses, Total 10.204 7.241 6.563 6.044 6.749
    Research & Development 15.601 22.063 19.014 14.11 13.821
    Unusual Expense (Income) 0 0 0 0 0
    Operating Income -25.805 -29.304 -25.577 -20.154 -20.57
    Interest Income (Expense), Net Non-Operating -0.234 -0.274 0.244 -1.004 -0.579
    Other, Net -29.658 5.562 -3.757 -0.441 -0.059
    Net Income Before Taxes -55.697 -24.016 -29.09 -21.599 -21.208
    Net Income After Taxes -55.712 -24.02 -29.104 -21.586 -21.212
    Net Income Before Extra. Items -55.712 -24.02 -29.104 -21.586 -21.212
    Net Income -55.712 -24.02 -29.104 -21.586 -21.212
    Total Adjustments to Net Income 0 0 0 -0.287 0
    Income Available to Common Excl. Extra. Items -55.712 -24.02 -29.104 -21.873 -21.212
    Income Available to Common Incl. Extra. Items -55.712 -24.02 -29.104 -21.873 -21.212
    Diluted Net Income -55.712 -24.02 -29.104 -21.873 -21.212
    Diluted Weighted Average Shares 168.738 145.967 101.176 83.211 35.437
    Diluted EPS Excluding Extraordinary Items -0.33017 -0.16456 -0.28766 -0.26286 -0.59858
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.33017 -0.16456 -0.28766 -0.26286 -0.59858
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 128.677 87.878 83.307 129.278 35.08
    Cash and Short Term Investments 121.718 81.787 78.708 126.184 30.754
    Cash 0.918
    Total Receivables, Net 1.152 0.747 0.917 1.998 2.859
    Prepaid Expenses 5.522 5.344 3.418 1.096 1.007
    Other Current Assets, Total 0.285 0 0.264 0.46
    Total Assets 155.586 117.176 122.871 160.698 36.004
    Property/Plant/Equipment, Total - Net 8.333 10.224 9.197 2.362 0.285
    Property/Plant/Equipment, Total - Gross 9.561 10.948 9.471 2.626 2.556
    Accumulated Depreciation, Total -1.228 -0.724 -0.274 -0.264 -2.271
    Other Long Term Assets, Total 1.225 1.723 3.258 1.949 0.639
    Total Current Liabilities 22.324 14.023 11.948 9.447 5.398
    Accounts Payable 7.777 4.283 3.144 2.088 0.545
    Accrued Expenses 13.232 8.945 8.804 7.359 4.116
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 1.315 0.795 0 0
    Other Current Liabilities, Total 0.737
    Total Liabilities 81.535 52.764 50.072 31.478 14.404
    Total Long Term Debt 32.304 33.139 33.178 20.097 7.894
    Long Term Debt 32.304 33.139 33.178 20.097 7.894
    Other Liabilities, Total 26.907 5.602 4.946 1.934 1.112
    Total Equity 74.051 64.412 72.799 129.22 21.6
    Redeemable Preferred Stock 0
    Common Stock 0.122 0.028 0.016 0.016 0.015
    Additional Paid-In Capital 450.786 347.374 267.077 261.367 156.63
    Retained Earnings (Accumulated Deficit) -376.738 -282.871 -194.175 -132.044 -135.286
    Other Equity, Total -0.119 -0.119 -0.119 -0.119 0.241
    Total Liabilities & Shareholders’ Equity 155.586 117.176 122.871 160.698 36.004
    Total Common Shares Outstanding 121.667 28.1277 16.3057 16.1289 2.42871
    Cash & Equivalents 121.718 81.787 78.708 126.184 29.836
    Goodwill, Net 17.351 17.351 27.109 27.109
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 147.872 147.649 98.222 128.677 85.718
    Cash and Short Term Investments 141.683 141.309 93.406 121.718 79.855
    Cash & Equivalents 131.581 136.428 93.406 121.718 79.855
    Total Receivables, Net 0.393 0.82 0.658 1.152 0.909
    Prepaid Expenses 5.546 5.27 3.908 5.807 4.954
    Total Assets 173.293 173.399 124.405 155.586 113.406
    Property/Plant/Equipment, Total - Net 6.826 7.32 7.83 8.333 8.8
    Property/Plant/Equipment, Total - Gross 8.411 8.801 9.185 9.561 9.904
    Accumulated Depreciation, Total -1.585 -1.481 -1.355 -1.228 -1.104
    Goodwill, Net 17.351 17.351 17.351 17.351 17.351
    Other Long Term Assets, Total 1.244 1.079 1.002 1.225 1.537
    Total Current Liabilities 25.432 22.251 19.483 22.324 28.713
    Accounts Payable 8.132 5.108 5.992 7.777 3.8
    Accrued Expenses 17.3 16.379 12.937 13.232 10.292
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 105.699 105.864 72.729 81.535 51.557
    Total Long Term Debt 54.322 31.836 31.827 32.304 18.733
    Long Term Debt 54.322 31.836 31.827 32.304 18.733
    Other Liabilities, Total 25.945 51.777 21.419 26.907 4.111
    Total Equity 67.594 67.535 51.676 74.051 61.849
    Common Stock 0.165 0.164 0.122 0.122 0.069
    Additional Paid-In Capital 526.323 523.96 452.431 450.786 409.533
    Retained Earnings (Accumulated Deficit) -458.775 -456.47 -400.758 -376.738 -347.634
    Other Equity, Total -0.119 -0.119 -0.119 -0.119 -0.119
    Total Liabilities & Shareholders’ Equity 173.293 173.399 124.405 155.586 113.406
    Total Common Shares Outstanding 164.706 164.418 122.207 121.667 68.7346
    Current Port. of LT Debt/Capital Leases 0 0.764 0.554 1.315 14.621
    Other Current Assets, Total 0.25 0.25 0.25
    Short Term Investments 10.102 4.881
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -93.867 -88.696 -62.131 -52.807 -43.021
    Cash From Operating Activities -77.102 -70.905 -58.818 -48.055 -40.903
    Cash From Operating Activities 0.513 0.499 0.351 0.103 0.155
    Non-Cash Items 10.516 18.79 7.025 7.885 6.424
    Changes in Working Capital 5.736 -1.498 -4.063 -3.236 -4.461
    Cash From Investing Activities -0.103 -0.615 -1.362 27.232 -0.034
    Capital Expenditures -0.103 -0.615 -1.362 -0.174 -0.034
    Cash From Financing Activities 117.23 74.245 12.394 140.661 -4.531
    Financing Cash Flow Items -4.814 0 -0.278 -0.043
    Issuance (Retirement) of Stock, Net 122.839 74.245 0.284 140.18 0.179
    Issuance (Retirement) of Debt, Net -0.795 0 12.388 0.481 -4.667
    Foreign Exchange Effects -0.105 -0.319 0.402 -0.25 -0.286
    Net Change in Cash 39.92 2.406 -47.384 119.588 -45.754
    Cash Interest Paid 3.006 2.906 2.099 1.284
    Other Investing Cash Flow Items, Total 0 0 27.406
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -24.02 -93.867 -64.763 -43.177 -21.965
    Cash From Operating Activities -26.512 -77.102 -58.009 -38.703 -20.229
    Cash From Operating Activities 0.127 0.513 0.389 0.265 0.133
    Non-Cash Items -3.235 10.516 6.104 3.818 1.903
    Changes in Working Capital 0.616 5.736 0.261 0.391 -0.3
    Cash From Investing Activities -0.009 -0.103 -0.069 -0.06 -0.022
    Capital Expenditures -0.009 -0.103 -0.069 -0.06 -0.022
    Cash From Financing Activities -2.124 117.23 56.586 4.609 4.956
    Issuance (Retirement) of Stock, Net -0.443 122.839 60.693 5.855 5.877
    Issuance (Retirement) of Debt, Net -1.681 -0.795 -0.795 -1.234 -0.909
    Foreign Exchange Effects 0.05 -0.105 -0.468 -0.271 -0.069
    Net Change in Cash -28.595 39.92 -1.96 -34.425 -15.364
    Financing Cash Flow Items 0 -4.814 -3.312 -0.012 -0.012
    Cash Interest Paid 3.006
    Other Investing Cash Flow Items, Total
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Bain Capital Life Sciences Investors, LLC Investment Advisor 9.7069 15960588 3758078 2023-06-30 LOW
    New Enterprise Associates (NEA) Venture Capital 9.1147 14986793 0 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.8311 7943565 7627005 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.736 7787140 3442829 2023-06-30 LOW
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 4.3385 7133515 1315789 2023-06-30 LOW
    Empery Asset Management, L.P. Investment Advisor/Hedge Fund 3.7699 6198684 6198684 2022-12-31 LOW
    Millennium Management LLC Hedge Fund 3.3156 5451610 4371397 2023-06-30 HIGH
    Polar Capital LLP Investment Advisor/Hedge Fund 3.0409 5000000 5000000 2023-06-30 LOW
    Stonepine Capital Management, LLC Investment Advisor/Hedge Fund 2.8008 4605263 4605263 2023-06-30 HIGH
    Adage Capital Management, L.P. Hedge Fund 2.6008 4276315 4276315 2023-06-30 LOW
    Tri Locum Partners LP Hedge Fund 2.4935 4099943 221459 2023-06-30 HIGH
    Parkman Healthcare Partners LLC Hedge Fund 2.2908 3766593 969446 2023-06-30
    Perceptive Advisors LLC Private Equity 2.1563 3545454 -1000000 2023-06-30 MED
    AXA Investment Managers UK Ltd. Investment Advisor/Hedge Fund 2.083 3424988 -971480 2023-06-30 LOW
    Citadel Advisors LLC Hedge Fund 1.8694 3073699 3055738 2023-06-30 LOW
    Armistice Capital LLC Hedge Fund 1.8099 2976000 2976000 2023-06-30 MED
    Medical Strategy GmbH Investment Advisor 1.6763 2756296 0 2023-05-31 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.4294 2350210 1241526 2023-06-30 LOW
    Heights Capital Management, Inc. Investment Advisor 1.399 2300315 2300315 2023-06-30 HIGH
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.3499 2219583 2048950 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    X4 Pharmaceuticals, Inc. Company profile

    About X4 Pharmaceuticals Inc

    X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of therapeutics for the treatment of rare diseases with an initial focus on the treatment of people with immune system dysfunction. Its lead product candidate, mavorixafor, is a small molecule inhibitor of the chemokine receptor CXCR4 and is being developed as a once-daily oral therapy. Its mavorixafor demonstrated ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells (WBCs), which provides therapeutic benefit across a variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Its mavorixafor is in a global Phase III clinical trial for the treatment of warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome, a rare, inherited PID caused by genetic mutations in the CXCR4 receptor gene. Its product candidates include X4P-001, X4P-002 and X4P-003.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, X4 Pharmaceuticals Inc revenues decreased from $3M to $0K. Net loss applicable to common stockholders increased 65% to $102.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 21% to $47.9M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    61 North Beacon Street
    4th Floor
    BOSTON
    MASSACHUSETTS 02134
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    US100

    15,794.40 Price
    -0.390% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Gold

    2,025.94 Price
    +0.400% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    Oil - Crude

    69.54 Price
    -3.700% 1D Chg, %
    Long position overnight fee -0.0207%
    Short position overnight fee -0.0013%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    BTC/USD

    43,950.85 Price
    +0.210% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading